In the fight to improve global health, we focus on six disease areas that have significant impact on people’s lives in the UK.

More focus, greater impact

We’ve streamlined our work by developing new innovative medicines for a core group of illnesses: cancer, gastro-intestinal, infection, respiratory and inflammation, neuroscience and cardiovascular.

In the UK, we invest around £1 billion each year in research and development, and through collaborations with the healthcare industry and its patients, we’re developing even more targeted medicines.

Cardiovascular & Diabetes

Cardiovascular diseases, including coronary heart disease and acute coronary syndrome, kill one in three people in the UK each year1. It is estimated that around 10% of the NHS budget is spent on diabetes2


In the West (i.e. Europe and North America) between 10-20% of adults suffer from gastro-oesophageal reflux disease (GORD)3.


Increasingly resistant to antibiotics, many infectious diseases continue to be a risk to global health.


UK cancer rates are expected to rise 45% by 20304, making our work in this area increasingly important.


Approval ID: 155,827.011
Date of preparation: June 2014


Our innovations in neuroscience include anesthetic treatments and medicines for mental illness and headaches disorders.

Respiratory & Inflammation

Over 5.4 million people in the UK have asthma5; so developing new treatments for this and other respiratory diseases is vital to improving lives.

For information about our medicines if you are a healthcare professional, visit our UK healthcare professionals resource website

For information about ordering Astrazeneca's products if you are a pharmacist, visit our medicines supply site